Click for best price
NonSmall Cell Lung Cancer Treatment NSCLC Market Size, Share 2023
This report contains market size and forecasts of Non-Small Cell Lung Cancer Treatment (NSCLC) in Global, including the following market information:
Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Revenue, 2018-2023, 2023-2032, ($ millions)
Global top five companies in 2022 (%)
The global Non-Small Cell Lung Cancer Treatment (NSCLC) market was valued at US$ million in 2022 and is projected to reach US$ million by 2032, at a CAGR of % during the forecast period 2023-2032.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million by 2032.
Angiogenesis Inhibitor Segment to Reach $ Million by 2032, with a % CAGR in next six years.
The global key manufacturers of Non-Small Cell Lung Cancer Treatment (NSCLC) include AbbVie Inc., Astellas Pharma, AstraZeneca, Avid Bioservices Inc., Bayer Healthcare, Biogen Inc., Blueprint Medicines Corp, Eli Lilly and Company and Merck & co Inc., etc. In 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Non-Small Cell Lung Cancer Treatment (NSCLC) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market, by Type, 2018-2023, 2023-2032 ($ millions)
Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Segment Percentages, by Type, 2022 (%)
Angiogenesis Inhibitor
Epidermal Growth Factor Receptor Blocker
Kinase Inhibitor
Microtubule Stabilizer
Folate Antimetabolites
Others
Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market, by Application, 2018-2023, 2023-2032 ($ millions)
Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Segment Percentages, by Application, 2022 (%)
Adenocarcinoma
Squamous Cell Carcinoma
Large Cell Carcinoma
Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market, By Region and Country, 2018-2023, 2023-2032 ($ Millions)
Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Non-Small Cell Lung Cancer Treatment (NSCLC) revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Non-Small Cell Lung Cancer Treatment (NSCLC) revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
AbbVie Inc.
Astellas Pharma
AstraZeneca
Avid Bioservices Inc.
Bayer Healthcare
Biogen Inc.
Blueprint Medicines Corp
Eli Lilly and Company
Merck & co Inc.
Novartis
Pfizer Inc.
| Report Attributes |
Report Details |
| Report Title |
Non-Small Cell Lung Cancer Treatment (NSCLC) Market, Global Outlook and Forecast 2023-2032 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
62 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Non-Small Cell Lung Cancer Treatment (NSCLC) Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Overall Market Size
2.1 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size: 2022 VS 2032
2.2 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, Prospects & Forecasts: 2018-2032
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Non-Small Cell Lung Cancer Treatment (NSCLC) Players in Global Market
3.2 Top Global Non-Small Cell Lung Cancer Treatment (NSCLC) Companies Ranked by Revenue
3.3 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue by Companies
3.4 Top 3 and Top 5 Non-Small Cell Lung Cancer Treatment (NSCLC) Companies in Global Market, by Revenue in 2022
3.5 Global Companies Non-Small Cell Lung Cancer Treatment (NSCLC) Product Type
3.6 Tier 1, Tier 2 and Tier 3 Non-Small Cell Lung Cancer Treatment (NSCLC) Players in Global Market
3.6.1 List of Global Tier 1 Non-Small Cell Lung Cancer Treatment (NSCLC) Companies
3.6.2 List of Global Tier 2 and Tier 3 Non-Small Cell Lung Cancer Treatment (NSCLC) Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size Markets, 2022 & 2032
4.1.2 Angiogenesis Inhibitor
4.1.3 Epidermal Growth Factor Receptor Blocker
4.1.4 Kinase Inhibitor
4.1.5 Microtubule Stabilizer
4.1.6 Folate Antimetabolites
4.1.7 Others
4.2 By Type - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue & Forecasts
4.2.1 By Type - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, 2018-2023
4.2.2 By Type - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, 2023-2032
4.2.3 By Type - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Market Share, 2018-2032
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2022 & 2032
5.1.2 Adenocarcinoma
5.1.3 Squamous Cell Carcinoma
5.1.4 Large Cell Carcinoma
5.2 By Application - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue & Forecasts
5.2.1 By Application - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, 2018-2023
5.2.2 By Application - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, 2023-2032
5.2.3 By Application - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Market Share, 2018-2032
6 Sights by Region
6.1 By Region - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2022 & 2032
6.2 By Region - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue & Forecasts
6.2.1 By Region - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, 2018-2023
6.2.2 By Region - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, 2023-2032
6.2.3 By Region - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Market Share, 2018-2032
6.3 North America
6.3.1 By Country - North America Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, 2018-2032
6.3.2 US Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2018-2032
6.3.3 Canada Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2018-2032
6.3.4 Mexico Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2018-2032
6.4 Europe
6.4.1 By Country - Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, 2018-2032
6.4.2 Germany Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2018-2032
6.4.3 France Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2018-2032
6.4.4 U.K. Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2018-2032
6.4.5 Italy Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2018-2032
6.4.6 Russia Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2018-2032
6.4.7 Nordic Countries Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2018-2032
6.4.8 Benelux Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2018-2032
6.5 Asia
6.5.1 By Region - Asia Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, 2018-2032
6.5.2 China Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2018-2032
6.5.3 Japan Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2018-2032
6.5.4 South Korea Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2018-2032
6.5.5 Southeast Asia Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2018-2032
6.5.6 India Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2018-2032
6.6 South America
6.6.1 By Country - South America Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, 2018-2032
6.6.2 Brazil Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2018-2032
6.6.3 Argentina Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2018-2032
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, 2018-2032
6.7.2 Turkey Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2018-2032
6.7.3 Israel Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2018-2032
6.7.4 Saudi Arabia Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2018-2032
6.7.5 UAE Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, 2018-2032
7 Players Profiles
7.1 AbbVie Inc.
7.1.1 AbbVie Inc. Corporate Summary
7.1.2 AbbVie Inc. Business Overview
7.1.3 AbbVie Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Major Product Offerings
7.1.4 AbbVie Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue in Global Market (2018-2023)
7.1.5 AbbVie Inc. Key News
7.2 Astellas Pharma
7.2.1 Astellas Pharma Corporate Summary
7.2.2 Astellas Pharma Business Overview
7.2.3 Astellas Pharma Non-Small Cell Lung Cancer Treatment (NSCLC) Major Product Offerings
7.2.4 Astellas Pharma Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue in Global Market (2018-2023)
7.2.5 Astellas Pharma Key News
7.3 AstraZeneca
7.3.1 AstraZeneca Corporate Summary
7.3.2 AstraZeneca Business Overview
7.3.3 AstraZeneca Non-Small Cell Lung Cancer Treatment (NSCLC) Major Product Offerings
7.3.4 AstraZeneca Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue in Global Market (2018-2023)
7.3.5 AstraZeneca Key News
7.4 Avid Bioservices Inc.
7.4.1 Avid Bioservices Inc. Corporate Summary
7.4.2 Avid Bioservices Inc. Business Overview
7.4.3 Avid Bioservices Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Major Product Offerings
7.4.4 Avid Bioservices Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue in Global Market (2018-2023)
7.4.5 Avid Bioservices Inc. Key News
7.5 Bayer Healthcare
7.5.1 Bayer Healthcare Corporate Summary
7.5.2 Bayer Healthcare Business Overview
7.5.3 Bayer Healthcare Non-Small Cell Lung Cancer Treatment (NSCLC) Major Product Offerings
7.5.4 Bayer Healthcare Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue in Global Market (2018-2023)
7.5.5 Bayer Healthcare Key News
7.6 Biogen Inc.
7.6.1 Biogen Inc. Corporate Summary
7.6.2 Biogen Inc. Business Overview
7.6.3 Biogen Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Major Product Offerings
7.6.4 Biogen Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue in Global Market (2018-2023)
7.6.5 Biogen Inc. Key News
7.7 Blueprint Medicines Corp
7.7.1 Blueprint Medicines Corp Corporate Summary
7.7.2 Blueprint Medicines Corp Business Overview
7.7.3 Blueprint Medicines Corp Non-Small Cell Lung Cancer Treatment (NSCLC) Major Product Offerings
7.7.4 Blueprint Medicines Corp Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue in Global Market (2018-2023)
7.7.5 Blueprint Medicines Corp Key News
7.8 Eli Lilly and Company
7.8.1 Eli Lilly and Company Corporate Summary
7.8.2 Eli Lilly and Company Business Overview
7.8.3 Eli Lilly and Company Non-Small Cell Lung Cancer Treatment (NSCLC) Major Product Offerings
7.8.4 Eli Lilly and Company Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue in Global Market (2018-2023)
7.8.5 Eli Lilly and Company Key News
7.9 Merck & co Inc.
7.9.1 Merck & co Inc. Corporate Summary
7.9.2 Merck & co Inc. Business Overview
7.9.3 Merck & co Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Major Product Offerings
7.9.4 Merck & co Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue in Global Market (2018-2023)
7.9.5 Merck & co Inc. Key News
7.10 Novartis
7.10.1 Novartis Corporate Summary
7.10.2 Novartis Business Overview
7.10.3 Novartis Non-Small Cell Lung Cancer Treatment (NSCLC) Major Product Offerings
7.10.4 Novartis Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue in Global Market (2018-2023)
7.10.5 Novartis Key News
7.11 Pfizer Inc.
7.11.1 Pfizer Inc. Corporate Summary
7.11.2 Pfizer Inc. Business Overview
7.11.3 Pfizer Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Major Product Offerings
7.11.4 Pfizer Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue in Global Market (2018-2023)
7.11.5 Pfizer Inc. Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Non-Small Cell Lung Cancer Treatment (NSCLC) Market Opportunities & Trends in Global Market
Table 2. Non-Small Cell Lung Cancer Treatment (NSCLC) Market Drivers in Global Market
Table 3. Non-Small Cell Lung Cancer Treatment (NSCLC) Market Restraints in Global Market
Table 4. Key Players of Non-Small Cell Lung Cancer Treatment (NSCLC) in Global Market
Table 5. Top Non-Small Cell Lung Cancer Treatment (NSCLC) Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Share by Companies, 2018-2023
Table 8. Global Companies Non-Small Cell Lung Cancer Treatment (NSCLC) Product Type
Table 9. List of Global Tier 1 Non-Small Cell Lung Cancer Treatment (NSCLC) Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Non-Small Cell Lung Cancer Treatment (NSCLC) Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2022 & 2032
Table 12. By Type - Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue in Global (US$, Mn), 2023-2032
Table 14. By Application ? Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2022 & 2032
Table 15. By Application - Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue in Global (US$, Mn), 2023-2032
Table 17. By Region ? Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2022 & 2032
Table 18. By Region - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue (US$, Mn), 2023-2032
Table 20. By Country - North America Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2023-2032
Table 22. By Country - Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2023-2032
Table 24. By Region - Asia Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2023-2032
Table 26. By Country - South America Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2023-2032
Table 28. By Country - Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2023-2032
Table 30. AbbVie Inc. Corporate Summary
Table 31. AbbVie Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Product Offerings
Table 32. AbbVie Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue (US$, Mn), (2018-2023)
Table 33. Astellas Pharma Corporate Summary
Table 34. Astellas Pharma Non-Small Cell Lung Cancer Treatment (NSCLC) Product Offerings
Table 35. Astellas Pharma Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue (US$, Mn), (2018-2023)
Table 36. AstraZeneca Corporate Summary
Table 37. AstraZeneca Non-Small Cell Lung Cancer Treatment (NSCLC) Product Offerings
Table 38. AstraZeneca Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue (US$, Mn), (2018-2023)
Table 39. Avid Bioservices Inc. Corporate Summary
Table 40. Avid Bioservices Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Product Offerings
Table 41. Avid Bioservices Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue (US$, Mn), (2018-2023)
Table 42. Bayer Healthcare Corporate Summary
Table 43. Bayer Healthcare Non-Small Cell Lung Cancer Treatment (NSCLC) Product Offerings
Table 44. Bayer Healthcare Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue (US$, Mn), (2018-2023)
Table 45. Biogen Inc. Corporate Summary
Table 46. Biogen Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Product Offerings
Table 47. Biogen Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue (US$, Mn), (2018-2023)
Table 48. Blueprint Medicines Corp Corporate Summary
Table 49. Blueprint Medicines Corp Non-Small Cell Lung Cancer Treatment (NSCLC) Product Offerings
Table 50. Blueprint Medicines Corp Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue (US$, Mn), (2018-2023)
Table 51. Eli Lilly and Company Corporate Summary
Table 52. Eli Lilly and Company Non-Small Cell Lung Cancer Treatment (NSCLC) Product Offerings
Table 53. Eli Lilly and Company Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue (US$, Mn), (2018-2023)
Table 54. Merck & co Inc. Corporate Summary
Table 55. Merck & co Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Product Offerings
Table 56. Merck & co Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue (US$, Mn), (2018-2023)
Table 57. Novartis Corporate Summary
Table 58. Novartis Non-Small Cell Lung Cancer Treatment (NSCLC) Product Offerings
Table 59. Novartis Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue (US$, Mn), (2018-2023)
Table 60. Pfizer Inc. Corporate Summary
Table 61. Pfizer Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Product Offerings
Table 62. Pfizer Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue (US$, Mn), (2018-2023)
List of Figures
Figure 1. Non-Small Cell Lung Cancer Treatment (NSCLC) Segment by Type in 2022
Figure 2. Non-Small Cell Lung Cancer Treatment (NSCLC) Segment by Application in 2022
Figure 3. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size: 2022 VS 2032 (US$, Mn)
Figure 6. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, 2018-2032 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue in 2022
Figure 8. By Type - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Market Share, 2018-2032
Figure 9. By Application - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Market Share, 2018-2032
Figure 10. By Region - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Market Share, 2018-2032
Figure 11. By Country - North America Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Market Share, 2018-2032
Figure 12. US Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2018-2032
Figure 13. Canada Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2018-2032
Figure 14. Mexico Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2018-2032
Figure 15. By Country - Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Market Share, 2018-2032
Figure 16. Germany Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2018-2032
Figure 17. France Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2018-2032
Figure 18. U.K. Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2018-2032
Figure 19. Italy Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2018-2032
Figure 20. Russia Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2018-2032
Figure 21. Nordic Countries Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2018-2032
Figure 22. Benelux Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2018-2032
Figure 23. By Region - Asia Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Market Share, 2018-2032
Figure 24. China Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2018-2032
Figure 25. Japan Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2018-2032
Figure 26. South Korea Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2018-2032
Figure 27. Southeast Asia Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2018-2032
Figure 28. India Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2018-2032
Figure 29. By Country - South America Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Market Share, 2018-2032
Figure 30. Brazil Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2018-2032
Figure 31. Argentina Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2018-2032
Figure 32. By Country - Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Market Share, 2018-2032
Figure 33. Turkey Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2018-2032
Figure 34. Israel Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2018-2032
Figure 35. Saudi Arabia Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2018-2032
Figure 36. UAE Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue, (US$, Mn), 2018-2032
Figure 37. AbbVie Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 38. Astellas Pharma Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 39. AstraZeneca Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 40. Avid Bioservices Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 41. Bayer Healthcare Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Biogen Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Blueprint Medicines Corp Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Eli Lilly and Company Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Merck & co Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Novartis Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Pfizer Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
